what clinical manifestations should you assess to correlate the left side of heart faliure

  • Periodical List
  • BMJ
  • v.320(7229); 2000 Jan 22
  • PMC1117436

BMJ. 2000 January 22; 320(7229): 236–239.

ABC of eye failure

Clinical features and complications

Clinical features

Patients with heart failure present with a variety of symptoms, most of which are non-specific. The common symptoms of congestive heart failure include fatigue, dyspnoea, bloated ankles, and exercise intolerance, or symptoms that relate to the underlying cause. The accuracy of diagnosis past presenting clinical features solitary, withal, is oftentimes inadequate, particularly in women and elderly or obese patients.

Symptoms and signs in heart failure

Symptoms

  • Dyspnoea

  • Orthopnoea

  • Paroxysmal nocturnal dyspnoea

  • Reduced exercise tolerance, lethargy, fatigue

  • Nocturnal cough

  • Wheeze

  • Ankle swelling

  • Anorexia

Signs

  • Cachexia and muscle wasting

  • Tachycardia

  • Pulsus alternans

  • Elevated jugular venous pressure

  • Displaced apex beat out

  • Right ventricular boost

  • Crepitations or wheeze

  • Tertiary eye sound

  • Oedema

  • Hepatomegaly (tender)

  • Ascites

Symptoms

Dyspnoea

Exertional breathlessness is a frequent presenting symptom in heart failure, although information technology is a mutual symptom in the general population, particularly in patients with pulmonary disease. Dyspnoea is therefore moderately sensitive, simply poorly specific, for the presence of heart failure. Orthopnoea is a more than specific symptom, although it has a low sensitivity and therefore has little predictive value. Paroxysmal nocturnal dyspnoea results from increased left ventricular filling pressures (due to nocturnal fluid redistribution and enhanced renal reabsorption) and therefore has a greater sensitivity and predictive value. Nocturnal ischaemic chest pain may too exist a manifestation of center failure, so left ventricular systolic dysfunction should be excluded in patients with recurrent nocturnal angina.

Common causes of lower limb oedema

  • Gravitational disorder—for example, immobility

  • Congestive middle failure

  • Venous thrombosis or obstruction, varicose veins

  • Hypoproteinaemia—for example, nephrotic syndrome, liver affliction

  • Lymphatic obstruction

Fatigue and lethargy

Fatigue and languor in chronic middle failure are, in function, related to abnormalities in skeletal muscle, with premature muscle lactate release, impaired muscle blood flow, scarce endothelial office, and abnormalities in skeletal muscle structure and function. Reduced cerebral claret flow, when accompanied by aberrant slumber patterns, may occasionally lead to somnolence and confusion in severe chronic center failure.

Sensitivity, specificity, and predictive value of symptoms, signs, and chest ten ray findings for presence of heart failure (ejection fraction <40%) in 1306 patients with coronary avenue disease undergoing cardiac catheterisation

    Clinical features   Sensitivity (%)   Specificity (%) Positive predictive value (%)




History:
 Shortness of breath 66 52 23
 Orthopnoea 21 81  2
 Paroxysmal nocturnal  dyspnoea 33 76 26
 History of oedema 23 80 22
Examination:
 Tachycardia (>100  beats/min)  7 99  half-dozen
 Crepitations 13 91 27
 Oedema (on  test) ten 93  3
 Gallop (S3) 31 95 61
 Cervix vein distension 10 97  2
Breast x ray examination:
 Cardiomegaly 62 67 32

Oedema

Swelling of ankles and feet is another common presenting feature, although there are numerous not-cardiac causes of this symptom. Correct heart failure may manifest as oedema, right hypochondrial pain (liver distension), abdominal swelling (ascites), loss of ambition, and, rarely, malabsorption (bowel oedema). An increase in weight may be associated with fluid retention, although cardiac cachexia and weight loss are of import markers of disease severity in some patients.

Physical signs

Physical exam has serious limitations equally many patients, particularly those with less severe centre failure, have few abnormal signs. In addition, some physical signs are difficult to interpret and, if present, may occasionally be related to causes other than eye failure.

Oedema and a tachycardia, for case, are besides insensitive to have whatsoever useful predictive value, and although pulmonary crepitations may have a high diagnostic specificity they have a low sensitivity and predictive value. Indeed, the commonest cause of lower limb oedema in elderly people is immobility, and pulmonary crepitations may reflect poor ventilation with infection, or pulmonary fibrosis, rather than heart failure. Jugular venous distension has a high specificity in diagnosing heart failure in patients who are known to have cardiac disease, although some patients, even with documented middle failure, exercise not accept an elevated venous pressure. The presence of a displaced apex shell in a patient with a history of myocardial infarction has a loftier positive predictive value. A 3rd centre sound has a relatively high specificity, although its universal value is limited past a high interobserver variability, with interobserver agreement of less than fifty% in not-specialists.

In patients with pre-existing chronic heart failure, other clinical features may be evident that point towards precipitating causes of acute eye failure or deteriorating heart failure. Common factors that may be obvious on clinical assessment and are associated with relapses in congestive center failure include infections, arrhythmias, connected or recurrent myocardial ischaemia, and anaemia.

Clinical diagnosis and clinical scoring systems

Several epidemiological studies, including the Framingham eye study, take used clinical scoring systems to define center failure, although the apply of these systems is not recommended for routine clinical do.

Precipitating causes of heart failure

  • Arrhythmias, especially atrial fibrillation

  • Infections (particularly pneumonia)

  • Astute myocardial infarction

  • Angina pectoris or recurrent myocardial ischaemia

  • Anaemia

  • Booze excess

  • Iatrogenic cause—for instance, postoperative fluid replacement or administration of steroids or non-steroidal anti-inflammatory drugs

  • Poor drug compliance, particularly in antihypertensive handling

  • Thyroid disorders—for example, thyrotoxicosis

  • Pulmonary embolism

  • Pregnancy

In a patient with advisable symptoms and a number of physical signs, including a displaced apex beat, elevated venous force per unit area, oedema, and a tertiary heart sound, the clinical diagnosis of heart failure may be made with some confidence. Still, the clinical suspicion of heart failure should also be confirmed with objective investigations and the demonstration of cardiac dysfunction at rest. It is important to note that, in some patients, exercise-induced myocardial ischaemia may atomic number 82 to a ascension in ventricular filling pressures and a autumn in cardiac output, leading to symptoms of eye failure during exertion.

Nomenclature

Symptoms and practise capacity are used to classify the severity of heart failure and monitor the response to treatment. The classification of the New York Heart Clan (NYHA) is used widely, although result in center failure is best adamant non simply past symptoms (NYHA course) merely also by echocardiographic criteria. Every bit the disease is progressive, the importance of early treatment, in an endeavor to forestall progression to more astringent illness, cannot be overemphasised.

European Gild of Cardiology's guidelines for diagnosis of heart failure

Essential features

  • Symptoms of heart failure (for instance, breathlessness, fatigue, ankle swelling)

  • and

  • Objective evidence of cardiac dysfunction (at residual)

Non-essential features

  • Response to handling directed towards eye failure (in cases where the diagnosis is in doubt)

Complications

Arrhythmias

Atrial fibrillation

Atrial fibrillation is present in about a third (range ten-50%) of patients with chronic middle failure and may represent either a cause or a consequence of centre failure. The onset of atrial fibrillation with a rapid ventricular response may precipitate overt heart failure, especially in patients with pre-existing ventricular dysfunction. Predisposing causes should be considered, including mitral valve disease, thyrotoxicosis, and sinus node disease. Chiefly, sinus node disease may be associated with bradycardias, which might be exacerbated past antiarrhythmic treatment.

NYHA nomenclature of heart failure

Class I: asymptomatic

No limitation in concrete activity despite presence of heart disease. This can be suspected just if there is a history of heart disease which is confirmed by investigations—for instance, echocardiography

Course II: mild

Slight limitation in physical activity. More strenuous activity causes shortness of breath—for instance, walking on steep inclines and several flights of steps. Patients in this grouping can go along to have an almost normal lifestyle and employment

Class III: moderate

More marked limitation of activeness which interferes with work. Walking on the flat produces symptoms

Class IV: astringent

Unable to carry out any concrete activity without symptoms. Patients are breathless at rest and mostly housebound

Atrial fibrillation that occurs with astringent left ventricular dysfunction following myocardial infarction is associated with a poor prognosis. In addition, patients with eye failure and atrial fibrillation are at particularly high take chances of stroke and other thromboembolic complications.

Ventricular arrhythmias

Malignant ventricular arrhythmias are mutual in end stage heart failure. For instance, sustained monomorphic ventricular tachycardia occurs in up to 10% of patients with avant-garde heart failure who are referred for cardiac transplantation. In patients with ischaemic heart disease these arrhythmias often have re-entrant mechanisms in scarred myocardial tissue. An episode of sustained ventricular tachycardia indicates a high risk for recurrent ventricular arrhythmias and sudden cardiac death.

Predisposing factors for ventricular arrhythmias

  • Recurrent or connected coronary ischaemia

  • Recurrent myocardial infarction

  • Hypokalaemia and hyperkalaemia

  • Hypomagnesaemia

  • Psychotropic drugs—for example, tricyclic antidepressants

  • Digoxin (leading to toxicity)

  • Antiarrhythmic drugs that may be cardiodepressant (negative inotropism) and proarrhythmic

Sustained polymorphic ventricular tachycardia and torsades de pointes are more probable to occur in the presence of precipitating or aggravating factors, including electrolyte disturbance (for example, hypokalaemia or hyperkalaemia, hypomagnesaemia), prolonged QT interval, digoxin toxicity, drugs causing electrical instability (for instance, antiarrhythmic drugs, antidepressants), and continued or recurrent myocardial ischaemia. β Blockers are useful for treating arrhythmias, and these agents (for example, bisoprolol, metoprolol, carvedilol) are probable to be increasingly used equally a treatment selection in patients with heart failure.

Stroke and thromboembolism

Congestive heart failure predisposes to stroke and thromboembolism, with an overall estimated almanac incidence of approximately 2%. Factors contributing to the increased thromboembolic risk in patients with middle failure include low cardiac output (with relative stasis of blood in dilated cardiac chambers), regional wall movement abnormalities (including formation of a left ventricular aneurysm), and associated atrial fibrillation. Although the prevalence of atrial fibrillation in some of the earlier observational studies was between 12% and 36%—which may have accounted for some of the thromboembolic events—patients with chronic heart failure who remain in sinus rhythm are also at an increased take chances of stroke and venous thromboembolism. Patients with center failure and chronic venous insufficiency may also be immobile, and this contributes to their increased gamble of thrombosis, including deep venous thrombosis and pulmonary embolism.

Complications of heart failure

  • Arrhythmias—Atrial fibrillation; ventricular arrhythmias (ventricular  tachycardia, ventricular fibrillation); bradyarrhythmias

  • Thromboembolism—Stroke; peripheral embolism; deep venous  thrombosis; pulmonary embolism

  • Gastrointestinal—Hepatic congestion and hepatic dysfunction;  malabsorption

  • Musculoskeletal—Muscle wasting

  • Respiratory—Pulmonary congestion; respiratory muscle weakness;  pulmonary hypertension (rare)

Recent observational data from the studies of left ventricular dysfunction (SOLVD) and vasodilator eye failure trials (Five-HeFT) indicate that mild to moderate middle failure is associated with an annual adventure of stroke of about 1.five% (compared with a risk of less than 0.5% in those without middle failure), rising to 4% in patients with astringent heart failure. In addition, the survival and ventricular enlargement (Salve) study recently reported an changed relation between take a chance of stroke and left ventricular ejection fraction, with an xviii% increase in risk for every v% reduction in left ventricular ejection fraction; this clearly relates thromboembolism to severe cardiac harm and the severity of eye failure. As thromboembolic gamble seems to be related to left atrial and left ventricular dilatation, echocardiography may take some function in the chance stratification of thromboembolism in patients with chronic heart failure.

Prognosis

Most long term (more than x years of follow up) longitudinal studies of middle failure, including the Framingham middle written report (1971), were performed before the widespread utilise of angiotensin converting enzyme inhibitors. In the Framingham report the overall survival at eight years for all NYHA classes was 30%, compared with a i year mortality in classes Three and IV of 34% and a one year bloodshed in class 4 of over sixty%. The prognosis in patients whose left ventricular dysfunction is asymptomatic is better than that in those whose left ventricular dysfunction is symptomatic. The prognosis in patients with congestive middle failure is dependent on severity, age, and sex activity, with a poorer prognosis in male patients. In addition, numerous prognostic indices are associated with an adverse prognosis, including NYHA class, left ventricular ejection fraction, and neurohormonal status.

Morbidity and bloodshed for all grades of symptomatic chronic heart failure are high, with a twenty-xxx% one twelvemonth mortality in balmy to moderate heart failure and a greater than 50% one year bloodshed in astringent center failure. These prognostic data refer to patients with systolic center failure, equally the natural course of diastolic dysfunction is less well defined

Some predictors of poor effect in chronic center failure

  • High NYHA functional class

  • Reduced left ventricular ejection fraction

  • Low elevation oxygen consumption with maximal exercise (% predicted value)

  • Third center sound

  • Increased pulmonary avenue capillary wedge pressure

  • Reduced cardiac index

  • Diabetes mellitus

  • Reduced sodium concentration

  • Raised plasma catecholamine and natriuretic peptide concentrations

Survival can exist prolonged in chronic middle failure that results from systolic dysfunction if angiotensin converting enzyme inhibitors are given. Longitudinal information from the Framingham study and the Mayo Clinic suggest, withal, that at that place is still simply a limited improvement in the one twelvemonth survival rate of patients with newly diagnosed symptomatic chronic heart failure, which remains at 60-70%. In these studies only a minority of patients with congestive heart failure were appropriately treated, with less than 25% of them receiving angiotensin converting enzyme inhibitors, and even among treated patients the dose used was much lower than doses used in the clinical trials.

Cardiac mortality in placebo controlled middle failure trials

      Trial     Patients' characteristics   Ischaemic heart disease (%)       Treatment Cardiovascular bloodshed     Follow up (years)






Treatment (%) Placebo (%)


CONSENSUS NYHA IV (cardiomegaly) 73 Enalapril 38 54 ane
SOLVD-P Asymptomatic (EF <35%) 83 Enalapril thirteen 14 four
SOLVD-T Symptomatic (EF <35%) 71 Enalapril 31 36 4
Save Postmyocardial infarction (EF <40%) 100 Captopril 17 21 iv
V-HeFT I NYHA II-Iii (EF <45%) 44 H-ISDN 37 41 5
V-HeFT II NYHA Ii-3 (EF <45%) 52 Enalapril 28  34* 5
PRAISE NYHA Iii-4 (EF <thirty%) 63 Amlodipine 28 33 1.2

EF ejection fraction. SOLVD-P, SOLVD-T=studies of left ventricular dysfunction prevention arm (P) and treatment arm (T).

H-ISDN=hydralazine and isosorbide dinitrate.

*Treatment with H-ISDN.

Handling with angiotensin converting enzyme inhibitors prevents or delays the onset of symptomatic heart failure in patients with asymptomatic, or minimally symptomatic, left ventricular systolic dysfunction. The increase in bloodshed with the evolution of symptoms suggests that the optimal time for intervention with these agents is well before the onset of substantial left ventricular dysfunction, even in the absence of overt clinical symptoms of heart failure. This benefit has been confirmed in several big, well conducted, postmyocardial infarction studies.

Key references

  • Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, et al. Randomised trial of low-dose amiodarone in severe congestive center failure. Lancet 1994;334:493-eight.

  • Gradman A, Deedwania P, Cody R, Massie B, Packer G, Pitt B, et al. Predictors of total mortality and sudden expiry in mild to moderate heart failure. J Am Coll Cardiol 1989;14:564-seventy.

  • Guidelines for the diagnosis of eye failure. The Job Force on Heart Failure of the European Society of Cardiology. Eur Middle J 1995;16:741-51.

  • Rodeheffer RJ, Jacobsen SJ, Gersh BJ, Kottke TE, McCann HA, Bailey KR, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993;68:1143-fifty.

  • The SOLVD Investigators. Effect of enalapril on mortality and the development of eye failure in asymptomatic patients with reduced left ventricular ejection fractions. Northward Engl J Med 1992;327:685-91.

  • The CONSENSUS Trial Study Group. Furnishings of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.

Sudden expiry

The mode of expiry in heart failure has been extensively investigated, and progressive middle failure and sudden expiry seem to occur with equal frequency. Some outstanding questions nonetheless remain, however. Although arrhythmias are common in patients with heart failure and are indicators of disease severity, they are not powerful contained predictors of prognosis. Sudden death may be related to ventricular arrhythmias, although asystole is a common terminal event in astringent heart failure. It has non been firmly established whether these arrhythmias are primary arrhythmias or whether some are secondary to acute coronary ischaemia or betoken in situ coronary thrombosis. The cause of death is oft uncertain, especially as the patient may die of a cardiac abort outside hospital or while asleep.

An external file that holds a picture, illustration, etc.  Object name is heart04.f1.jpg

Gross oedema of ankles, including bullae with serous exudate

An external file that holds a picture, illustration, etc.  Object name is heart04.f2.jpg

24 Hour Holter tracing showing frequent ventricular extrasystoles

Acknowledgments

The table on the sensitivity, specificity, and predictive value of symptoms, signs, and chest x ray findings is adapted with permission from Harlan et al (Ann Intern Med 1977;86:133-eight).

Footnotes

R D Southward Watson is consultant cardiologist in the university department of medicine and the section of cardiology, Metropolis Hospital, Birmingham.

The ABC of heart failure is edited by C R Gibbs, M K Davies, and G Y H Lip. CRG is research fellow and GYHL is consultant cardiologist and reader in medicine in the university department of medicine and the department of cardiology, Metropolis Hospital, Birmingham; MKD is consultant cardiologist in the department of cardiology, Selly Oak Hospital, Birmingham. The series will be published as a volume in the spring.


Articles from The BMJ are provided here courtesy of BMJ Publishing Group


acostaanny1962.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1117436/

0 Response to "what clinical manifestations should you assess to correlate the left side of heart faliure"

Post a Comment

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel